Dr. Andrew Miller is a highly accomplished biopharmaceutical executive with expertise in research and development and corporate strategy. Dr. Miller founded and built a leading neuroscience company, Karuna Therapeutics, from concept to IPO, FDA approval, and a $14B acquisition. Most recently, Dr. Miller was the Founder and President of R&D at Karuna Therapeutics. He was the lead inventor of Karuna’s KarXT, now marketed as COBENFY for treatment of schizophrenia, and previously served as Chief Operating Officer, Chief Executive Officer, and as a member of Karuna’s Board of Directors.

Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics and as an advisor to Google Ventures, General Atlantic, Vida Ventures, Longwood Fund, and the One Mind Foundation. Dr. Miller was recently named to Time Magazine’s 100 Next Generation Leaders, and 100 Most Influential People in Healthcare for 2025, and was also named to the Fierce 50 for 2025.

He holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the University of Illinois at Urbana-Champaign.